Trials & Filings

Antarex MTX Auto-Injector Reaches Market

Otrexup approved in October 2013 for RA, pJIA

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Antares Pharma has made available Otrexup, the first FDA-approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. Otrexup was approved by the FDA in October 2013 and is available at distribution centers throughout the U.S. Otrexup is indicated for adults with severe active rheumatoid arthritis (RA) who have had an insufficient therapeutic response to or are intolerant of an adequate trial of first line ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters